dihydroxyphenylalanine has been researched along with Parkinsonian Disorders in 57 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Persistent dyskinesias in the absence of or with only minimal amounts of dopaminergic medication have been reported after dopamine cell implantation for Parkinson's disease." | 2.70 | Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. ( Breeze, R; Dhawan, V; Eidelberg, D; Fahn, S; Feigin, A; Freed, C; Fukuda, M; Greene, P; Ma, Y; Shi, Q, 2002) |
| "With respect to Parkinson's disease PET and later SPECT allowed the number of dopaminergic neurons to be assessed in vivo." | 2.46 | [Nuclear medicine imaging in patients with Parkinson's syndrome: an update]. ( Schwarz, J, 2010) |
| "Two subjects presented with action tremor around age 10-12 years and developed tremor-dominant parkinsonism with prominent neuropsychiatric features later in their 20s." | 1.72 | WARS2 mutations cause dopa-responsive early-onset parkinsonism and progressive myoclonus ataxia. ( Berutti, R; Bonifati, V; Boumeester, V; Brunet, T; Gdovinova, Z; Han, V; Havrankova, P; Houlden, H; Jech, R; Kaiyrzhanov, R; Kuipers, DJS; Kulcsarova, K; Lackova, A; Mandemakers, W; Orec, L; Ostrozovicova, M; Pavelekova, P; Plecko, B; Rektorova, I; Rizig, M; Skorvanek, M; Steinfeld, R; Tijssen, MAJ; Wagner, M; Winkelmann, J; Zech, M, 2022) |
| "28 subjects had idiopathic Parkinson's disease (14 male, 14 female; age at scan 61 +- 11,5), 13 atypical Parkinsonian disease (7 male, 6 females; age at scan: 69,6 +- 6,4) and 17 were controls (6 male, 11 female; age at scan 65,3 +-8,6)." | 1.56 | Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders. ( Chaves, LT; De Jong, BM; Dierckx, RAJO; Doorduin, J; Kremer, BPH; Leenders, KL; Stormezand, GN; Vállez García, D, 2020) |
| " The loaded gel was administered in different doses and dosing regimens to Parkinsonian rats, and the catalepsy score and striatal DA levels were assessed." | 1.42 | Potential efficacy of dopamine loaded-PVP/PAA nanogel in experimental models of Parkinsonism: possible disease modifying activity. ( Abd El-Rehim, HA; El-Ghazaly, MA; Rashed, ER, 2015) |
| "Levodopa and placebo treated animals exhibited a similar number of surviving dopaminergic cells in the SN." | 1.40 | Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway. ( Arbizu, J; Collantes, M; DiCaudo, C; Luquin, MR; Marcilla, I; Ordóñez, C; Peñuelas, I; Riverol, M, 2014) |
| " The long-term use of LD is limited by the development of L-DOPA-induced dyskinesias and dystonia." | 1.39 | The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia. ( Aley-Medina, P; Anaya-Martínez, V; Avila-Costa, MR; Espinosa-Villanueva, J; García-Ruiz, R; Gutiérrez-Valdez, AL; Montiel-Flores, E; Reynoso-Erazo, L; Sánchez-Betancourt, J; Torres-Esquivel, C; Tron-Alvarez, R, 2013) |
| " Study of pharmacokinetic parameters (AUC, C(max), and T(max)) revealed a greater and more extended release of ropinirole from nanoemulsion gel compared to that from a conventional gel (RPG) and oral marketed tablet (Ropitor)." | 1.38 | Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. ( Ahmad, FJ; Azeem, A; Iqbal, Z; Khar, RK; Negi, LM; Talegaonkar, S, 2012) |
| "The third part of the unified Parkinson's disease rating scale (UPDRS) was used to evaluate the development of PD symptom before and 1 hour after taking the medicine." | 1.35 | [Acute dopaminergic responsiveness test in diagnosis of Parkinson's disease and Parkinsonian disorders]. ( Feng, T; Li, W; Lin, JX; Wang, YJ; Xu, XT, 2008) |
| "This tremor was refractory to gabapentin and dramatically responded to Levodopa administration." | 1.34 | Dopa-responsive pseudo-orthostatic tremor in parkinsonism. ( Antonini, A; Barone, P; Bonanni, L; Onofrj, M; Thomas, A, 2007) |
| "Parkinsonism was induced using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine." | 1.32 | Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. ( Bezard, E; Di Monte, DA; Hsu, A; Langston, JW; Quik, M; Sokoloff, P; Togasaki, DM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (24.56) | 18.7374 |
| 1990's | 1 (1.75) | 18.2507 |
| 2000's | 22 (38.60) | 29.6817 |
| 2010's | 11 (19.30) | 24.3611 |
| 2020's | 9 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Eisenberg, DP | 1 |
| Lopez, G | 1 |
| Gregory, MD | 1 |
| Berman, KF | 1 |
| Sidransky, E | 1 |
| Skorvanek, M | 1 |
| Rektorova, I | 1 |
| Mandemakers, W | 1 |
| Wagner, M | 1 |
| Steinfeld, R | 1 |
| Orec, L | 1 |
| Han, V | 1 |
| Pavelekova, P | 1 |
| Lackova, A | 1 |
| Kulcsarova, K | 1 |
| Ostrozovicova, M | 1 |
| Gdovinova, Z | 1 |
| Plecko, B | 1 |
| Brunet, T | 1 |
| Berutti, R | 1 |
| Kuipers, DJS | 1 |
| Boumeester, V | 1 |
| Havrankova, P | 1 |
| Tijssen, MAJ | 1 |
| Kaiyrzhanov, R | 1 |
| Rizig, M | 1 |
| Houlden, H | 1 |
| Winkelmann, J | 1 |
| Bonifati, V | 1 |
| Zech, M | 1 |
| Jech, R | 1 |
| Goldfarb, L | 1 |
| Iep, A | 1 |
| Chawki, MB | 1 |
| Nguyen, L | 1 |
| Lun, F | 1 |
| Carpentier, AAN | 1 |
| de Recondo, A | 1 |
| Blin, J | 1 |
| Bourdinaud, V | 1 |
| Morin, L | 1 |
| Andriatsiferana, H | 1 |
| Ferreira, A | 1 |
| Deschiens, AM | 1 |
| Brulon, V | 1 |
| Comtat, C | 1 |
| Lebon, V | 1 |
| Besson, FL | 1 |
| Lim, SY | 1 |
| Tan, AH | 1 |
| Tay, YW | 1 |
| Stormezand, GN | 1 |
| Chaves, LT | 1 |
| Vállez García, D | 1 |
| Doorduin, J | 1 |
| De Jong, BM | 1 |
| Leenders, KL | 1 |
| Kremer, BPH | 1 |
| Dierckx, RAJO | 1 |
| da Silva Schmitt, G | 1 |
| Martinez, ARM | 1 |
| da Graça, FF | 1 |
| de Lima, FD | 1 |
| Bonadia, LC | 1 |
| Amorim, BJ | 1 |
| Nucci, A | 1 |
| França, MC | 1 |
| Sood, A | 1 |
| Shukla, J | 1 |
| Shree, R | 1 |
| Vatsa, R | 1 |
| Modi, M | 1 |
| Mittal, BR | 1 |
| Speck, AE | 1 |
| Aguiar, AS | 1 |
| Ferreira, SG | 1 |
| Silva, HB | 1 |
| Tomé, ÂR | 1 |
| Agostinho, P | 1 |
| Cunha, RA | 1 |
| Prediger, RD | 1 |
| Guo, Q | 1 |
| Wang, B | 1 |
| Wang, X | 1 |
| Smith, WW | 1 |
| Zhu, Y | 1 |
| Liu, Z | 1 |
| Criswell, SR | 1 |
| Nielsen, SS | 1 |
| Warden, M | 1 |
| Perlmutter, JS | 1 |
| Moerlein, SM | 1 |
| Flores, HP | 1 |
| Huang, J | 1 |
| Sheppard, L | 1 |
| Seixas, N | 1 |
| Checkoway, H | 1 |
| Racette, BA | 1 |
| Wu, J | 1 |
| Zhao, YM | 1 |
| Deng, ZK | 1 |
| Riverol, M | 1 |
| Ordóñez, C | 1 |
| Collantes, M | 1 |
| DiCaudo, C | 1 |
| Peñuelas, I | 1 |
| Arbizu, J | 1 |
| Marcilla, I | 1 |
| Luquin, MR | 1 |
| Gutiérrez-Valdez, AL | 1 |
| García-Ruiz, R | 1 |
| Anaya-Martínez, V | 1 |
| Torres-Esquivel, C | 1 |
| Espinosa-Villanueva, J | 1 |
| Reynoso-Erazo, L | 1 |
| Tron-Alvarez, R | 1 |
| Aley-Medina, P | 1 |
| Sánchez-Betancourt, J | 1 |
| Montiel-Flores, E | 1 |
| Avila-Costa, MR | 1 |
| Rashed, ER | 1 |
| Abd El-Rehim, HA | 1 |
| El-Ghazaly, MA | 1 |
| Darcourt, J | 1 |
| Schiazza, A | 1 |
| Sapin, N | 1 |
| Dufour, M | 1 |
| Ouvrier, MJ | 1 |
| Benisvy, D | 1 |
| Fontana, X | 1 |
| Koulibaly, PM | 1 |
| Goldstein, DS | 1 |
| Holmes, C | 1 |
| Sharabi, Y | 1 |
| Wu, T | 1 |
| Li, W | 1 |
| Feng, T | 1 |
| Wang, YJ | 1 |
| Lin, JX | 1 |
| Xu, XT | 1 |
| Lipton, J | 1 |
| Rivkin, MJ | 1 |
| Björklund, T | 1 |
| Hall, H | 1 |
| Breysse, N | 1 |
| Soneson, C | 1 |
| Carlsson, T | 1 |
| Mandel, RJ | 1 |
| Carta, M | 1 |
| Kirik, D | 1 |
| Schwarz, J | 1 |
| Azeem, A | 1 |
| Talegaonkar, S | 1 |
| Negi, LM | 1 |
| Ahmad, FJ | 1 |
| Khar, RK | 1 |
| Iqbal, Z | 1 |
| Joutsa, J | 1 |
| Martikainen, K | 1 |
| Niemelä, S | 1 |
| Johansson, J | 1 |
| Forsback, S | 1 |
| Rinne, JO | 1 |
| Kaasinen, V | 1 |
| Walker, MD | 1 |
| Dinelle, K | 1 |
| Kornelsen, R | 1 |
| McCormick, S | 1 |
| Mah, C | 1 |
| Holden, JE | 2 |
| Farrer, MJ | 1 |
| Stoessl, AJ | 2 |
| Sossi, V | 1 |
| Kock, N | 1 |
| Müller, B | 1 |
| Vieregge, P | 1 |
| Pramstaller, PP | 1 |
| Marder, K | 1 |
| Abbruzzese, G | 1 |
| Martinelli, P | 1 |
| Lang, AE | 1 |
| Jacobs, H | 1 |
| Hagenah, J | 1 |
| Harris, J | 1 |
| Meija-Santana, H | 1 |
| Fahn, S | 2 |
| Hedrich, K | 2 |
| Kann, M | 1 |
| Gehlken, U | 1 |
| Culjkovic, B | 1 |
| Schwinger, E | 1 |
| Wszolek, ZK | 1 |
| Zühlke, C | 1 |
| Klein, C | 2 |
| Pal, PK | 1 |
| Leung, J | 1 |
| Samii, A | 1 |
| Lieberman, A | 1 |
| Nausieda, PA | 1 |
| Calne, DB | 1 |
| Breakefield, XO | 1 |
| Ma, Y | 1 |
| Feigin, A | 1 |
| Dhawan, V | 1 |
| Fukuda, M | 1 |
| Shi, Q | 1 |
| Greene, P | 1 |
| Breeze, R | 1 |
| Freed, C | 1 |
| Eidelberg, D | 1 |
| Huang, WS | 1 |
| Ma, KH | 1 |
| Chou, YH | 1 |
| Chen, CY | 1 |
| Liu, RS | 1 |
| Liu, JC | 1 |
| BIRKMAYER, W | 2 |
| HORNYKIEWICZ, O | 2 |
| GERSTENBRAND, F | 1 |
| PATEISKY, K | 1 |
| PROSENZ, P | 1 |
| MCGEER, PL | 1 |
| ZELDOWICZ, LR | 1 |
| UMBACH, W | 1 |
| BAUMANN, D | 1 |
| TRAVENED, I | 1 |
| TRAVENEC, I | 1 |
| SCHULTE, W | 1 |
| HIRSCHMANN, J | 2 |
| MAYER, K | 2 |
| DESCHAEPDRYVER, A | 1 |
| SOURKES, TL | 1 |
| PIVNICKI, D | 1 |
| BROWN, WT | 1 |
| WISEMAN-DISTLER, H | 1 |
| MURPHY, GF | 1 |
| SANKOFF, I | 1 |
| SAINTCYR, S | 1 |
| DIEMATH, HE | 1 |
| HEPPNER, F | 1 |
| ENGE, S | 1 |
| LECHNER, H | 1 |
| LAVERTY, R | 1 |
| SHARMAN, DF | 1 |
| Fontan, A | 1 |
| Rojo, A | 1 |
| Sanchez Pernaute, R | 1 |
| Hernández, I | 1 |
| López, I | 1 |
| Castilla, C | 1 |
| Sanchez Albisua, J | 1 |
| Perez Higueras, A | 1 |
| Al-Rashid, I | 1 |
| Rabano, A | 1 |
| Gonzalo, I | 1 |
| Angeles Mena, M | 1 |
| Cools, A | 1 |
| Eshuis, S | 1 |
| Maguire, P | 1 |
| Pruim, J | 1 |
| Leenders, K | 1 |
| Garcia de Yebenes, J | 1 |
| Kishima, H | 1 |
| Poyot, T | 1 |
| Bloch, J | 2 |
| Dauguet, J | 1 |
| Condé, F | 1 |
| Dollé, F | 1 |
| Hinnen, F | 1 |
| Pralong, W | 1 |
| Palfi, S | 2 |
| Déglon, N | 2 |
| Aebischer, P | 2 |
| Hantraye, P | 2 |
| Hsu, A | 1 |
| Togasaki, DM | 2 |
| Bezard, E | 1 |
| Sokoloff, P | 1 |
| Langston, JW | 2 |
| Di Monte, DA | 1 |
| Quik, M | 1 |
| Doudet, DJ | 1 |
| Cornfeldt, ML | 1 |
| Honey, CR | 1 |
| Schweikert, AW | 1 |
| Allen, RC | 1 |
| Honer, M | 1 |
| Hengerer, B | 1 |
| Blagoev, M | 1 |
| Hintermann, S | 1 |
| Waldmeier, P | 1 |
| Schubiger, PA | 1 |
| Ametamey, SM | 1 |
| Thomas, A | 1 |
| Bonanni, L | 1 |
| Antonini, A | 1 |
| Barone, P | 1 |
| Onofrj, M | 1 |
| Seibyl, JP | 1 |
| Chen, W | 1 |
| Silverman, DH | 1 |
| Abe, Y | 1 |
| Kachi, T | 1 |
| Kato, T | 1 |
| Ito, K | 1 |
| Yanagisawa, N | 1 |
| Sobue, G | 1 |
| Kordower, JH | 1 |
| Emborg, ME | 1 |
| Ma, SY | 1 |
| Chu, Y | 1 |
| Leventhal, L | 1 |
| McBride, J | 1 |
| Chen, EY | 1 |
| Roitberg, BZ | 1 |
| Brown, WD | 1 |
| Pyzalski, R | 1 |
| Taylor, MD | 1 |
| Carvey, P | 1 |
| Ling, Z | 1 |
| Trono, D | 1 |
| Chekhonin, VP | 1 |
| Baklaushev, VP | 1 |
| Kogan, BM | 1 |
| Savchenko, EA | 1 |
| Lebedev, SV | 1 |
| Man'kovskaya, IV | 1 |
| Filatova, TS | 1 |
| Yusupova, IU | 1 |
| Dmitrieva, TB | 1 |
| Cumming, P | 2 |
| Danielsen, EH | 1 |
| Vafaee, M | 1 |
| Falborg, L | 1 |
| Steffensen, E | 1 |
| Sørensen, JC | 1 |
| Gillings, N | 1 |
| Bender, D | 1 |
| Marthi, K | 1 |
| Andersen, F | 1 |
| Munk, O | 1 |
| Smith, D | 1 |
| Møller, A | 1 |
| Gjedde, A | 1 |
| Munk, OL | 1 |
| Doudet, D | 1 |
| Yee, RE | 1 |
| Irwin, I | 1 |
| Milonas, C | 1 |
| Stout, DB | 1 |
| Huang, SC | 1 |
| Shoghi-Jadid, K | 1 |
| Satyamurthy, N | 1 |
| Delanney, LE | 1 |
| Farahani, KF | 1 |
| Delfani, K | 1 |
| Janson, AM | 1 |
| Phelps, ME | 1 |
| Barrio, JR | 1 |
| Thobois, S | 1 |
| Guillouet, S | 1 |
| Broussolle, E | 1 |
| Yoshimura, M | 1 |
| Yamamoto, T | 1 |
| Iso-o, N | 1 |
| Imafuku, I | 1 |
| Momose, T | 1 |
| Shirouzu, I | 1 |
| Kwak, S | 1 |
| Kanazawa, I | 1 |
| Ishihara, K | 1 |
| Nonaka, A | 1 |
| Fukui, T | 1 |
| Kawamura, M | 1 |
| Shiota, J | 1 |
| Nakano, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Embryonic Dopamine Cell Implants for Parkinson's Disease: A Double-Blind Study[NCT00038116] | Phase 3 | 40 participants (Actual) | Interventional | 1995-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for dihydroxyphenylalanine and Parkinsonian Disorders
| Article | Year |
|---|---|
18F-FDOPA PET for the diagnosis of parkinsonian syndromes.
Topics: Brain; Dihydroxyphenylalanine; Disease Progression; Humans; Image Processing, Computer-Assisted; Par | 2014 |
[Nuclear medicine imaging in patients with Parkinson's syndrome: an update].
Topics: Animals; Brain; Dihydroxyphenylalanine; Disease Progression; Dopamine; Energy Metabolism; Fluorodeox | 2010 |
[PSYCHOPHARMACA: OBSERVATIONS AND INTERPRETATIONS].
Topics: Amphetamine; Amphetamines; Caudate Nucleus; Central Nervous System Stimulants; Chlorpromazine; Dihyd | 1964 |
3,4-dihydroxy-6-[18f]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors.
Topics: Adrenal Gland Neoplasms; Amino Acids; Brain Neoplasms; Caudate Nucleus; Dihydroxyphenylalanine; Fluo | 2007 |
Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
Topics: Aging; Animals; Antiparkinson Agents; Basal Ganglia; Brain Tissue Transplantation; Cell Transplantat | 2001 |
1 trial available for dihydroxyphenylalanine and Parkinsonian Disorders
| Article | Year |
|---|---|
Dyskinesia after fetal cell transplantation for parkinsonism: a PET study.
Topics: Adult; Brain; Caudate Nucleus; Cohort Studies; Dihydroxyphenylalanine; Double-Blind Method; Dyskines | 2002 |
51 other studies available for dihydroxyphenylalanine and Parkinsonian Disorders
| Article | Year |
|---|---|
Comparison of Transcranial Sonography and [
Topics: Dihydroxyphenylalanine; Dopamine; Glucosylceramidase; Humans; Mutation; Parkinsonian Disorders; Posi | 2022 |
WARS2 mutations cause dopa-responsive early-onset parkinsonism and progressive myoclonus ataxia.
Topics: Ataxia; Dihydroxyphenylalanine; Humans; Mutation; Myoclonus; Parkinsonian Disorders; Phenotype; Spin | 2022 |
Head-to-Head Comparison Between Rabbit Sign and EANM/SNMMI Criteria for the 18F-DOPA Visual Assessment of Parkinsonian Syndromes in PET/MRI: A Multiple Expert-Based and Blinded Controlled Study.
Topics: Animals; Dihydroxyphenylalanine; Humans; Magnetic Resonance Imaging; Parkinsonian Disorders; Positro | 2023 |
Deep brain stimulation in Dopa-Responsive Parkinsonism - Look out for red flags: Expert commentary.
Topics: Deep Brain Stimulation; Dihydroxyphenylalanine; Humans; Parkinson Disease; Parkinsonian Disorders | 2023 |
Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders.
Topics: Aged; Caudate Nucleus; Corpus Striatum; Diagnosis, Differential; Dihydroxyphenylalanine; Female; Hum | 2020 |
Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
Topics: Atrophy; Dihydroxyphenylalanine; Homozygote; Humans; Multiple System Atrophy; Parkinsonian Disorders | 2020 |
Comparative Performance of 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT Imaging in Patients With Parkinson's Disease, Parkinson-Plus Syndrome, and Essential Tremor.
Topics: Dihydroxyphenylalanine; Essential Tremor; Female; Humans; Male; Middle Aged; Organotechnetium Compou | 2021 |
Exercise decreases aberrant corticostriatal plasticity in an animal model of l-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benserazide; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine | 2021 |
Activation of Nrf2 in Astrocytes Suppressed PD-Like Phenotypes via Antioxidant and Autophagy Pathways in Rat and Drosophila Models.
Topics: Adenine; Animals; Animals, Genetically Modified; Antioxidants; Antiparkinson Agents; Astrocytes; Aut | 2021 |
[
Topics: Adult; Corpus Striatum; Cross-Sectional Studies; Dihydroxyphenylalanine; Female; Humans; Magnetic Re | 2018 |
Neuroprotective action and mechanistic evaluation of protodioscin against rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Brain; Cell Line, Tumor; Cognition; Dihydroxyphenylalanine; Diosgenin; Di | 2018 |
Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
Topics: Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Dihydroxypheny | 2014 |
The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Administration, Oral; Animals; Cannabinoid Receptor Antagonists; Corpus Striatum; Dihydroxyphenylala | 2013 |
Potential efficacy of dopamine loaded-PVP/PAA nanogel in experimental models of Parkinsonism: possible disease modifying activity.
Topics: Acrylic Resins; Animals; Catalepsy; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Male; | 2015 |
Survival in synucleinopathies: A prospective cohort study.
Topics: Aged; alpha-Synuclein; Brain; Cerebellar Diseases; Cohort Studies; Dihydroxyphenylalanine; Female; F | 2015 |
[Acute dopaminergic responsiveness test in diagnosis of Parkinson's disease and Parkinsonian disorders].
Topics: Adult; Aged; Diagnosis, Differential; Dihydroxyphenylalanine; Dopamine; Female; Humans; Male; Middle | 2008 |
16p11.2-related paroxysmal kinesigenic dyskinesia and dopa-responsive parkinsonism in a child.
Topics: Adolescent; Chromosomes, Human, Pair 16; Dihydroxyphenylalanine; Dyskinesias; Humans; Male; Middle A | 2009 |
Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats.
Topics: Animals; Biopterins; Corpus Striatum; Dependovirus; Dihydroxyphenylalanine; Dopamine; Female; Geneti | 2009 |
Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Antiparkinson Agents; Biological Availabil | 2012 |
Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders.
Topics: Aged; Compulsive Behavior; Dihydroxyphenylalanine; Disruptive, Impulse Control, and Conduct Disorder | 2012 |
In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET.
Topics: Animals; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Fluorine Radiois | 2013 |
Role of SCA2 mutations in early- and late-onset dopa-responsive parkinsonism.
Topics: Age of Onset; Ataxins; Dihydroxyphenylalanine; Dopamine Agents; Drug Resistance; Humans; Nerve Tissu | 2002 |
[18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism.
Topics: Adolescent; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; DNA Mutational Analysis; Domin | 2002 |
99mTc-TRODAT-1 SPECT in healthy and 6-OHDA lesioned parkinsonian monkeys: comparison with 18F-FDOPA PET.
Topics: Animals; Corpus Striatum; Dihydroxyphenylalanine; Macaca; Metabolic Clearance Rate; Models, Animal; | 2003 |
[The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: On the pathogenesis and treatment of Parkinson akinesis].
Topics: Dihydroxyphenylalanine; Humans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinsonian | 1962 |
[EXPERIENCES WITH L-DOPA IN THE THERAPY OF PARKINSONISM].
Topics: Dihydroxyphenylalanine; Humans; Levodopa; Parkinsonian Disorders | 1963 |
ADMINISTRATION OF DIHYDROXYPHENYLALANINE TO PARKINSONIAN PATIENTS.
Topics: Dihydroxyphenylalanine; Dopamine; Extrapyramidal Tracts; Geriatrics; Humans; Injections, Intravenous | 1964 |
[THE EFFICACY OF L-DOPA IN PARKINSON PATIENTS WITH AND WITHOUT STEREOTACTIC BRAIN SURGERY].
Topics: Brain; Dihydroxyphenylalanine; Levodopa; Neurosurgery; Neurosurgical Procedures; Parkinsonian Disord | 1964 |
[PATHOGENESIS OF THE BASIC SYMPTOMS OF PARKINSONISM DUE TO BIOCHEMICAL CHANGES IN THE SUBCORTICAL AND STEM STRUCTURES OF THE EXTRAPYRAMIDAL SYSTEM].
Topics: Brain; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Extrapyramidal Tracts; Humans; Microsco | 1964 |
[PATHOGENESIS OF THE BASIC SYMPTOMS OF PARKINSONISM DUE TO BIOCHEMICAL CHANGES IN THE SUBCORTICAL AND STEM STRUCTURES OF THE EXTRAPYRAMIDAL SYSTEM].
Topics: Brain; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Extrapyramidal Tracts; Humans; Microsco | 1964 |
[PSYCHIATRIC UNIVERSITY CLINIC AND PSYCHIATRIC STATE HOSPITAL].
Topics: Aging; Brain Diseases; Dihydroxyphenylalanine; Germany; Germany, West; Hospitals, Psychiatric; Hospi | 1964 |
[ON THE CONTROL OF AKINESIA AND OTHER EXTRAPYRAMIDAL MOTOR DISORDERS WITH L-DOPA (L-DIHYDROXYPHENYLALANINE)].
Topics: Chorea; Dihydroxyphenylalanine; Electromyography; Extrapyramidal Tracts; Humans; Levodopa; Monoamine | 1964 |
[NEW MEANS OF CONTROLLING EXTRAPYRAMIDAL MOTOR DISORDERS].
Topics: Central Nervous System Diseases; Dihydroxyphenylalanine; Drug Therapy; Electroencephalography; Extra | 1964 |
A CLINICAL AND METABOLIC STUDY OF DOPA (3, 4-DIHYDROXYPHENYLALANINE) AND METHYLDOPA IN HUNTINGTON'S CHOREA.
Topics: Body Fluids; Chorea; Dihydroxyphenylalanine; Drug Therapy; Electroencephalography; Fluids and Secret | 1965 |
[ELECTROENCEPHALOGRAMS DURING ADMINISTRATION OF L-DOPA BEFORE, IN (DEPTH LEADS AND STIMULATION EFFECTS) AND AFTER STEREOTACTIC BRAIN OPERATIONS IN PARKINSON PATIENTS].
Topics: Brain; Dihydroxyphenylalanine; Electroencephalography; Levodopa; Neurosurgery; Neurosurgical Procedu | 1964 |
MODIFICATION BY DRUGS OF THE METABOLISM OF 3,4-DIHYDROXYPHENYLETHYLAMINE, NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THE BRAIN.
Topics: Animals; Atropine; Behavior, Animal; Brain; Brain Chemistry; Cats; Caudate Nucleus; Cerebral Cortex; | 1965 |
[ADDITIONAL EXPERIMENTAL STUDIES ON L-DOPA IN PARKINSON'S SYNDROME AND RESERPINE PARKINSONISM].
Topics: Biomedical Research; Brain; Catecholamines; Dihydroxyphenylalanine; Levodopa; Metabolism; Parkinson | 1964 |
Effects of fibroblast growth factor and glial-derived neurotrophic factor on akinesia, F-DOPA uptake and dopamine cells in parkinsonian primates.
Topics: Animals; Cell Count; Dihydroxyphenylalanine; Dopamine; Fibroblast Growth Factor 2; Fluorine Radioiso | 2002 |
Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons.
Topics: Animals; Capsules; Dihydroxyphenylalanine; Fluorine Radioisotopes; Genetic Therapy; Glial Cell Line- | 2004 |
Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys.
Topics: Animals; Dihydroxyphenylalanine; Disease Models, Animal; Drug Interactions; Dyskinesias; Female; Par | 2004 |
PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease.
Topics: Animals; Binding, Competitive; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Female; Hum | 2004 |
Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice.
Topics: Animals; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Male; Mice; Mice, Inbred C57BL; Neurotra | 2006 |
Dopa-responsive pseudo-orthostatic tremor in parkinsonism.
Topics: Adult; Dihydroxyphenylalanine; Dopamine Agents; Female; Humans; Male; Middle Aged; Parkinsonian Diso | 2007 |
[Diagnostic utility of positron emission tomography for parkinsonism after chronic manganese exposure].
Topics: Diagnosis, Differential; Dihydroxyphenylalanine; Fluorine Radioisotopes; Humans; Male; Manganese Poi | 1999 |
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Antigens, CD; Dihydroxyphenylalanine; | 2000 |
Catecholamines and their metabolites in the brain and urine of rats with experimental Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catecholamines; Dihydroxyphenylalanine; Dopamine; Ep | 2000 |
Normalization of markers for dopamine innervation in striatum of MPTP-lesioned miniature pigs with intrastriatal grafts.
Topics: Animals; Antineoplastic Agents; Dihydroxyphenylalanine; Dopamine; Graft Survival; Isoquinolines; Par | 2001 |
Loss of metabolites from monkey striatum during PET with FDOPA.
Topics: Animals; Blood-Brain Barrier; Denervation; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Flu | 2001 |
Novel observations with FDOPA-PET imaging after early nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dihydroxyphenylalanine; Dise | 2001 |
Hemiparkinsonism associated with a mesencephalic tumor.
Topics: Brain Stem Neoplasms; Carbon Radioisotopes; Caudate Nucleus; Dihydroxyphenylalanine; Dopamine Agents | 2002 |
Lewy body-free nigral degeneration--a case report.
Topics: Aged; Dihydroxyphenylalanine; Fatal Outcome; Female; Humans; Lewy Bodies; Nerve Degeneration; Parkin | 2002 |